Company Information

  

Address: 201 MISSION STREET, SUITE 2375  
City: SAN FRANCISCO 
State: CA 
Zip Code: 94105 
Telephone: 415-896-5081 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia is our lead prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. We achieved statistically significant results in a multicenter canine proof-of-concept study completed in February 2015, supporting the conclusion that Canalevia treatment is superior to placebo. As we announced in December 2015, the pivotal clinical field study to evaluate the safety and effectiveness of Canalevia for acute diarrhea in dogs is underway. Two-hundred dogs were enrolled in the Canalevia pivotal study, which completed enrollment in January 2017. Jaguar has received Minor Use in a Minor Species (MUMS) designation for Canalevia for Chemotherapy-Induced Diarrhea (CID) in dogs.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.02NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.39Total Liab/Total Assets1.69
Net Inc/Total Assets-4.14Total Liab/Inv Cap-2.23
Net Inc/Inv Cap5.46Total Liab/Comm Equity0.16
Pretax Inc/Net Sales-104.11Interest Coverage Ratio-13.95
Net Inc/Net Sales-104.11Curr Debt/Equity-0.84
Cash Flow/Net Sales-101.85LTD/Equity-0.74
SG&A/NetSales45.71Total Debt/Equity-1.58
Asset Utilization   Liquidity  
Net Receivables Turnover0.78Quick Ratio0.51
Inventory Turnover0.16Current Ratio0.61
Inventory Day Sales0.00Net Rec/Curr Assets0.12
Net Sales/Work Cap-0.09Inv/Curr Assets0.16
Net Sales/PP&E0.16  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.90 0.82 0.03 0.05
Cost of Goods Sold 0.02 0.02 0.02 0.01
Selling & Admin Exps 2.30 3.43 1.79 1.25
Operating Income -2.35 -3.88 -3.31 -3.18
Interest Exp 0.16 0.18 0.21 0.24
Pretax Income -1.81 -4.72 -3.68 -3.42
Other Income 0.70 -0.66 -0.15 -0.00
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -1.81 -4.72 -3.68 -3.42

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 2.76 1.23 1.46 2.80
Receivables - Total 0.43 0.51 0.30 0.28
Inventories - Total 0.40 0.39 0.41 0.28
Total Current Assets 3.96 2.58 2.56 4.08
Net Property, Plant & Equipment 0.86 0.87 0.89 0.90
Total Assets 4.94 3.57 3.56 5.10
Liabilities        
Accounts Payable 4.30 2.73 1.10 0.85
Debt in Current Liabilities 3.87 2.14 2.07 2.00
Total Current Liabilities 10.36 8.43 4.19 3.10
Long-Term Debt 0.84 1.33 1.82 2.27
Total Liabilities 11.21 9.77 6.02 5.37
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -46.96 -45.15 -40.44 -36.76
Treasury Stock NA NA NA NA
Total Stockholders' Equity -6.27 -6.19 -2.45 -0.27
Total Liabilities and Stockholders' Equity 4.94 3.57 3.56 5.10

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -1.18 -0.29 -2.73 -3.38
Net Cash Provided by Investing Activities 0.02 0.49 0.48 0.15
Net Cash Provided by Financing Activities 2.71 0.05 1.39 1.17

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20140.00-8.61--
12/20150.26-16.29--
12/20160.14-14.73--
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17124,80919.61




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.